Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Non-Current Assets (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Other Non-Current Assets for 5 consecutive years, with $2.9 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Assets rose 68.99% year-over-year to $2.9 million; the TTM value through Mar 2026 reached $2.9 million, up 68.99%, while the annual FY2025 figure was $2.9 million, 72.3% up from the prior year.
  • Other Non-Current Assets hit $2.9 million in Q1 2026 for Phathom Pharmaceuticals, down from $2.9 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.8 million in Q3 2023 and bottomed at $299000.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $2.0 million, with a median of $1.7 million recorded in 2024.
  • On a YoY basis, Other Non-Current Assets climbed as much as 467.72% in 2024 and fell as far as 54.87% in 2024.
  • Phathom Pharmaceuticals' Other Non-Current Assets stood at $299000.0 in 2022, then skyrocketed by 465.89% to $1.7 million in 2023, then increased by 0.06% to $1.7 million in 2024, then skyrocketed by 72.3% to $2.9 million in 2025, then decreased by 1.92% to $2.9 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $2.9 million, $2.9 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.